Functional OCT4-specific CD4⁺ and CD8⁺ T cells in healthy controls and ovarian cancer patients

References

• Rutkowski MR, Stephen TL, Conejo-Garcia JR. Anti-tumor immunity: myeloid leukocytes control the immune landscape. Cell Immunol 2012; 278:21 - 6; http://dx.doi.org/10.1016/j.cellimm.2012.06.014; PMID: 23121972
   PubMed Web of Science ®Google Scholar
• Preston CC, Goode EL, Hartmann LC, Kalli KR, Knutson KL. Immunity and immune suppression in human ovarian cancer. Immunotherapy 2011; 3:539 - 56; http://dx.doi.org/10.2217/imt.11.20; PMID: 21463194
   PubMed Web of Science ®Google Scholar
• Galon J, Pagès F, Marincola FM, Thurin M, Trinchieri G, Fox BA, et al. The immune score as a new possible approach for the classification of cancer. J Transl Med 2012; 10:1; http://dx.doi.org/10.1186/1479-5876-10-1; PMID: 22214470
   PubMed Web of Science ®Google Scholar
• Bamias A, Koutsoukou V, Terpos E, Tsiatas ML, Liakos C, Tsitsilonis O, et al. Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy. Gynecol Oncol 2008; 108:421 - 7; http://dx.doi.org/10.1016/j.ygyno.2007.10.018; PMID: 18036640
   PubMed Web of Science ®Google Scholar
• Papamichail M, Perez SA, Gritzapis AD, Baxevanis CN. Natural killer lymphocytes: biology, development, and function. Cancer Immunol Immunother 2004; 53:176 - 86; http://dx.doi.org/10.1007/s00262-003-0478-4; PMID: 14685782
   PubMed Web of Science ®Google Scholar
• Nagorsen D, Scheibenbogen C, Marincola FM, Letsch A, Keilholz U. Natural T cell immunity against cancer. Clin Cancer Res 2003; 9:4296 - 303; PMID: 14555498
   PubMed Web of Science ®Google Scholar
• Zhao T, Zhang Z-N, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature 2011; 474:212 - 5; http://dx.doi.org/10.1038/nature10135; PMID: 21572395
   PubMed Web of Science ®Google Scholar
• Renkvist N, Castelli C, Robbins PF, Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 2001; 50:3 - 15; http://dx.doi.org/10.1007/s002620000169; PMID: 11315507
   PubMed Web of Science ®Google Scholar
• Wolfl M, Kuball J, Ho WY, Nguyen H, Manley TJ, Bleakley M, et al. Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood 2007; 110:201 - 10; http://dx.doi.org/10.1182/blood-2006-11-056168; PMID: 17371945
   PubMed Web of Science ®Google Scholar
• Cannons JL, Lau P, Ghumman B, DeBenedette MA, Yagita H, Okumura K, et al. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. J Immunol 2001; 167:1313 - 24; PMID: 11466348
   PubMed Web of Science ®Google Scholar
• Wen T, Bukczynski J, Watts TH. 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function. J Immunol 2002; 168:4897 - 906; PMID: 11994439
   PubMed Web of Science ®Google Scholar
• Trapani JA, Smyth MJ. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol 2002; 2:735 - 47; http://dx.doi.org/10.1038/nri911; PMID: 12360212
   PubMed Web of Science ®Google Scholar
• Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, Roederer M, et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003; 281:65 - 78; http://dx.doi.org/10.1016/S0022-1759(03)00265-5; PMID: 14580882
   PubMed Web of Science ®Google Scholar
• Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 2004; 75:163 - 89; http://dx.doi.org/10.1189/jlb.0603252; PMID: 14525967
   PubMed Web of Science ®Google Scholar
• Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100:3983 - 8; http://dx.doi.org/10.1073/pnas.0530291100; PMID: 12629218
   PubMed Web of Science ®Google Scholar
• Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3:730 - 7; http://dx.doi.org/10.1038/nm0797-730; PMID: 9212098
   PubMed Web of Science ®Google Scholar
• Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65:10946 - 51; http://dx.doi.org/10.1158/0008-5472.CAN-05-2018; PMID: 16322242
   PubMed Web of Science ®Google Scholar
• Curley MD, Therrien VA, Cummings CL, Sergent PA, Koulouris CR, Friel AM, et al. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells 2009; 27:2875 - 83; PMID: 19816957
   PubMed Web of Science ®Google Scholar
• Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A 2007; 104:10158 - 63; http://dx.doi.org/10.1073/pnas.0703478104; PMID: 17548814
   PubMed Web of Science ®Google Scholar
• Dieter SM, Ball CR, Hoffmann CM, Nowrouzi A, Herbst F, Zavidij O, et al. Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. Cell Stem Cell 2011; 9:357 - 65; http://dx.doi.org/10.1016/j.stem.2011.08.010; PMID: 21982235
   PubMed Web of Science ®Google Scholar
• Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005; 65:9328 - 37; http://dx.doi.org/10.1158/0008-5472.CAN-05-1343; PMID: 16230395
   PubMed Web of Science ®Google Scholar
• Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1:313 - 23; http://dx.doi.org/10.1016/j.stem.2007.06.002; PMID: 18371365
   PubMed Web of Science ®Google Scholar
• Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature 2008; 456:593 - 8; http://dx.doi.org/10.1038/nature07567; PMID: 19052619
   PubMed Web of Science ®Google Scholar
• Rasheed Z, Wang Q, Matsui W. Isolation of stem cells from human pancreatic cancer xenografts. J Vis Exp 2010; http://dx.doi.org/10.3791/2169; PMID: 20972397
   PubMedGoogle Scholar
• Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63:5821 - 8; PMID: 14522905
   PubMed Web of Science ®Google Scholar
• Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008; 68:4311 - 20; http://dx.doi.org/10.1158/0008-5472.CAN-08-0364; PMID: 18519691
   PubMed Web of Science ®Google Scholar
• Looijenga LH, Stoop H, de Leeuw HP, de Gouveia Brazao CA, Gillis AJ, van Roozendaal KE, et al. POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res 2003; 63:2244 - 50; PMID: 12727846
   PubMed Web of Science ®Google Scholar
• Medvedev SP, Shevchenko AI, Mazurok NA, Zakiian SM. [OCT4 and NANOG are the key genes in the system of pluripotency maintenance in mammalian cells]. Genetika 2008; 44:1589 - 608; PMID: 19178078
   PubMedGoogle Scholar
• Zangrossi S, Marabese M, Broggini M, Giordano R, D’Erasmo M, Montelatici E, et al. Oct-4 expression in adult human differentiated cells challenges its role as a pure stem cell marker. Stem Cells 2007; 25:1675 - 80; http://dx.doi.org/10.1634/stemcells.2006-0611; PMID: 17379765
   PubMed Web of Science ®Google Scholar
• Jones TD, Ulbright TM, Eble JN, Baldridge LA, Cheng L. OCT4 staining in testicular tumors: a sensitive and specific marker for seminoma and embryonal carcinoma. Am J Surg Pathol 2004; 28:935 - 40; http://dx.doi.org/10.1097/00000478-200407000-00014; PMID: 15223965
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV. Immunity to stemness genes in human cancer. Curr Opin Immunol 2010; 22:245 - 50; http://dx.doi.org/10.1016/j.coi.2010.01.011; PMID: 20144857
   PubMed Web of Science ®Google Scholar
• Dhodapkar KM, Feldman D, Matthews P, Radfar S, Pickering R, Turkula S, et al. Natural immunity to pluripotency antigen OCT4 in humans. Proc Natl Acad Sci U S A 2010; 107:8718 - 23; http://dx.doi.org/10.1073/pnas.0915086107; PMID: 20404147
   PubMed Web of Science ®Google Scholar
• Li Y, Kurlander RJ. Comparison of anti-CD3 and anti-CD28-coated beads with soluble anti-CD3 for expanding human T cells: differing impact on CD8 T cell phenotype and responsiveness to restimulation. J Transl Med 2010; 8:104; http://dx.doi.org/10.1186/1479-5876-8-104; PMID: 20977748
   PubMed Web of Science ®Google Scholar
• Hatano R, Ohnuma K, Yamamoto J, Dang NH, Morimoto C. CD26-mediated co-stimulation in human CD8(+) T cells provokes effector function via pro-inflammatory cytokine production. Immunology 2013; 138:165 - 72; PMID: 23113658
   PubMed Web of Science ®Google Scholar
• Wang HY, Wang RF. Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling. Adv Immunol 2012; 114:151 - 76; http://dx.doi.org/10.1016/B978-0-12-396548-6.00006-8; PMID: 22449781
   PubMed Web of Science ®Google Scholar
• Bakker AB, Schreurs MW, de Boer AJ, Kawakami Y, Rosenberg SA, Adema GJ, et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 1994; 179:1005 - 9; http://dx.doi.org/10.1084/jem.179.3.1005; PMID: 8113668
   PubMed Web of Science ®Google Scholar
• Nijman HW, Van der Burg SH, Vierboom MP, Houbiers JG, Kast WM, Melief CJ. p53, a potential target for tumor-directed T cells. Immunol Lett 1994; 40:171 - 8; http://dx.doi.org/10.1016/0165-2478(94)90189-9; PMID: 8088874
   PubMed Web of Science ®Google Scholar
• Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 1995; 154:3961 - 8; PMID: 7706734
   PubMed Web of Science ®Google Scholar
• Salgaller ML, Afshar A, Marincola FM, Rivoltini L, Kawakami Y, Rosenberg SA. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res 1995; 55:4972 - 9; PMID: 7585538
   PubMed Web of Science ®Google Scholar
• Disis ML, Knutson KL, McNeel DG, Davis D, Schiffman K. Clinical translation of peptide-based vaccine trials: the HER-2/neu model. Crit Rev Immunol 2001; 21:263 - 73; http://dx.doi.org/10.1615/CritRevImmunol.v21.i1-3.170; PMID: 11642608
   PubMed Web of Science ®Google Scholar
• Mercader M, Bodner BK, Moser MT, Kwon PS, Park ES, Manecke RG, et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A 2001; 98:14565 - 70; http://dx.doi.org/10.1073/pnas.251140998; PMID: 11734652
   PubMed Web of Science ®Google Scholar
• Lesterhuis WJ, Aarntzen EH, De Vries IJ, Schuurhuis DH, Figdor CG, Adema GJ, et al. Dendritic cell vaccines in melanoma: from promise to proof?. Crit Rev Oncol Hematol 2008; 66:118 - 34; http://dx.doi.org/10.1016/j.critrevonc.2007.12.007; PMID: 18262431
   PubMed Web of Science ®Google Scholar
• Schuurhuis DH, Verdijk P, Schreibelt G, Aarntzen EH, Scharenborg N, de Boer A, et al. In situ expression of tumor antigens by messenger RNA-electroporated dendritic cells in lymph nodes of melanoma patients. Cancer Res 2009; 69:2927 - 34; http://dx.doi.org/10.1158/0008-5472.CAN-08-3920; PMID: 19318559
   PubMed Web of Science ®Google Scholar
• Aarntzen EH, Bol K, Schreibelt G, Jacobs JF, Lesterhuis WJ, Van Rossum MM, et al. Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma. Cancer Res 2012; 72:6102 - 10; http://dx.doi.org/10.1158/0008-5472.CAN-12-2479; PMID: 23010076
   PubMed Web of Science ®Google Scholar
• Van Nuffel AM, Benteyn D, Wilgenhof S, Pierret L, Corthals J, Heirman C, et al. Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients. Mol Ther 2012; 20:1063 - 74; http://dx.doi.org/10.1038/mt.2012.11; PMID: 22371843
   PubMed Web of Science ®Google Scholar
• Oshita C, Takikawa M, Kume A, Miyata H, Ashizawa T, Iizuka A, et al. Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial. Oncol Rep 2012; 28:1131 - 8; PMID: 22895835
   PubMed Web of Science ®Google Scholar
• Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogava M, Cron M, et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature 2012; 490:412 - 6; http://dx.doi.org/10.1038/nature11538; PMID: 23051752
   PubMed Web of Science ®Google Scholar
• Labidi-Galy SI, Sisirak V, Meeus P, Gobert M, Treilleux I, Bajard A, et al. Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. Cancer Res 2011; 71:5423 - 34; http://dx.doi.org/10.1158/0008-5472.CAN-11-0367; PMID: 21697280
   PubMed Web of Science ®Google Scholar
• Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 2006; 203:871 - 81; http://dx.doi.org/10.1084/jem.20050930; PMID: 16606666
   PubMed Web of Science ®Google Scholar
• Yigit R, Massuger LF, Figdor CG, Torensma R. Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol Oncol 2010; 117:366 - 72; http://dx.doi.org/10.1016/j.ygyno.2010.01.019; PMID: 20144842
   PubMed Web of Science ®Google Scholar
• Kryczek I, Wei S, Zhu G, Myers L, Mottram P, Cheng P, et al. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res 2007; 67:8900 - 5; http://dx.doi.org/10.1158/0008-5472.CAN-07-1866; PMID: 17875732
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942 - 9; http://dx.doi.org/10.1038/nm1093; PMID: 15322536
   PubMed Web of Science ®Google Scholar
• Dhodapkar KM, Feldman D, Matthews P, Radfar S, Pickering R, Turkula S, et al. Natural immunity to pluripotency antigen OCT4 in humans. Proc Natl Acad Sci U S A 2010; 107:8718 - 23; http://dx.doi.org/10.1073/pnas.0915086107; PMID: 20404147
   PubMed Web of Science ®Google Scholar
• Spisek R, Kukreja A, Chen LC, Matthews P, Mazumder A, Vesole D, et al. Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. J Exp Med 2007; 204:831 - 40; http://dx.doi.org/10.1084/jem.20062387; PMID: 17389240
   PubMed Web of Science ®Google Scholar
• Kobold S, Tams S, Luetkens T, Cao Y, Sezer O, Bartels BM, Reinhard H, Templin J, Bartels K, Hildebrandt Y, Lajmi N, Marx A, Haag F, Bokemeyer C, Kroger N, Atanackovic D. Patients with multiple myeloma develop SOX2-specific autoantibodies after allogeneic stem cell transplantation. Clin Dev Immunol 2011; 2011:302145.
   Google Scholar
• Zhao P, Liu C, Xu K, Zheng S, Li H, Xu Y, et al. [Expression of OCT4 protein in bladder cancer and its clinicopathological implications]. Nan Fang Yi Ke Da Xue Xue Bao 2012; 32:643 - 6; PMID: 22588915
   PubMedGoogle Scholar
• Xu K, Zhu Z, Zeng F. Expression and significance of Oct4 in bladder cancer. J Huazhong Univ Sci Technolog Med Sci 2007; 27:675 - 7; http://dx.doi.org/10.1007/s11596-007-0614-z; PMID: 18231740
   PubMed Web of Science ®Google Scholar
• Singh S, Trevino JG, Bora-Singhal N, Coppola D, Haura E, Altiok S, et al. EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer. Mol Cancer 2012; 11:73; http://dx.doi.org/10.1186/1476-4598-11-73; PMID: 23009336
   PubMed Web of Science ®Google Scholar
• Bourguignon LY, Wong G, Earle C, Chen L. Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma. J Biol Chem 2012; 287:32800 - 24; http://dx.doi.org/10.1074/jbc.M111.308528; PMID: 22847005
   PubMed Web of Science ®Google Scholar
• Riggi N, Suvà ML, De Vito C, Provero P, Stehle JC, Baumer K, et al. EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells. Genes Dev 2010; 24:916 - 32; http://dx.doi.org/10.1101/gad.1899710; PMID: 20382729
   PubMed Web of Science ®Google Scholar
• Zhao S, Yuan Q, Hao H, Guo Y, Liu S, Zhang Y, et al. Expression of OCT4 pseudogenes in human tumours: lessons from glioma and breast carcinoma. J Pathol 2011; 223:672 - 82; http://dx.doi.org/10.1002/path.2827; PMID: 21341266
   PubMed Web of Science ®Google Scholar
• Guo Y, Liu S, Wang P, Zhao S, Wang F, Bing L, et al. Expression profile of embryonic stem cell-associated genes Oct4, Sox2 and Nanog in human gliomas. Histopathology 2011; 59:763 - 75; http://dx.doi.org/10.1111/j.1365-2559.2011.03993.x; PMID: 22014056
   PubMed Web of Science ®Google Scholar
• Prud’homme GJ. Cancer stem cells and novel targets for antitumor strategies. Curr Pharm Des 2012; 18:2838 - 49; PMID: 22390767
   PubMed Web of Science ®Google Scholar
• Tsai L-L, Yu C-C, Chang Y-C, Yu C-H, Chou M-Y. Markedly increased Oct4 and Nanog expression correlates with cisplatin resistance in oral squamous cell carcinoma. J Oral Pathol Med 2011; 40:621 - 8; http://dx.doi.org/10.1111/j.1600-0714.2011.01015.x; PMID: 21342274
   PubMed Web of Science ®Google Scholar
• Hu L, McArthur C, Jaffe RB. Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br J Cancer 2010; 102:1276 - 83; http://dx.doi.org/10.1038/sj.bjc.6605626; PMID: 20354527
   PubMed Web of Science ®Google Scholar
• Gao MQ, Choi YP, Kang S, Youn JH, Cho NH. CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene 2010; 29:2672 - 80; http://dx.doi.org/10.1038/onc.2010.35; PMID: 20190812
   PubMed Web of Science ®Google Scholar
• Zhi-Iong Ma J, Yang J, Qin JS, Richter A, Perret R, El-Deiry WS, et al. Inefficient boosting of antitumor CD8(+) T cells by dendritic-cell vaccines is rescued by restricting T-cell cytotoxic functions. Oncoimmunology 2012; 1:1507 - 16; http://dx.doi.org/10.4161/onci.22128; PMID: 23264897
   PubMed Web of Science ®Google Scholar